Advancement in the 21st century is revolutionizing medicine to be more precise and clinically tailored for individual patients. While we are equipped with more efficient drugs, choosing the right drug choice for a specific subgroup of patients is still an active area of research. In the past few years, more reports have shown that ethnicity contributes significantly towards the heterogeneous drug response. Understanding how the genetic backgrounds are associated with commonly observed variability in therapeutic sensitivity will help fulfill this critical research gap. Systems Pharmacology is a new discipline that is gaining attentions in the international research community. Focusing on quantitative reasoning and the investigation of drug mechanisms from the cellular level upto the population level, Systems Pharmacology helps advance drug discovery and development in a network-centric fashion. Realizing the potentials of this new research paradigm, the Faculty of Medicine Siriraj Hospital, as a leading medical research institute in Thailand, has launched a new research program called the Siriraj Initiative in Systems Pharmacology (SiSP) in 2015 to fulfill this research need. Led by two young pioneers, Dr.Somponnat Sampattavanich and Dr.Siwanon Jirawatnotai both ex-Bostonian researchers, SiSP is designed from its start to be a multidisciplinary, collaborative and resourceful incubator for talented Thai scientists. To dates, there are already over 40 active researchers from both inside and outside Siriraj that are working under the SiSP program. Current research activities range from investigation of prognostic biomarkers for cancer treatment to whole-genome screening of proteins that are responsible for Orientia tsutsugamushi infection in scrub typhus. The core instrument at SiSP is the high-content imaging platform for high-throughput phenotypic screening and proteomic measurement. This technology enables quantitative measurement of single-cell heterogeneity up to over 10,000 data points per day. Other core technologies include the development of advanced biosensor for live measurement of signaling network activity and point-of-care diagnostics. These cutting edge technology will provide the necessary foundations for the next generation of Thai pharmaceutical industry.